Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 3/20 | 0.43 |
| ▸ | PPARA | Q07869 | 3/20 | 0.43 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.42 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HMGCR | P04035 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27375877 | 0.88 | TYR (0.45) | HSP90AB1PPARAPOLBMEN1LMNA | |
| SCHEMBL7044950 | 0.88 | HPGD (0.49) | CYSLTR2CYSLTR1MEN1LMNAMAPT | |
| SCHEMBL11393041 | 0.86 | MAPT (0.40) | HSP90AB1PPARGPPARACYSLTR2CYSLTR1 | |
| SCHEMBL8957148 | 0.86 | PRKCI (0.41) | HSP90AB1PPARGPPARACYSLTR2CYSLTR1 | |
| SCHEMBL27711763 | 0.85 | HSP90AB1 (0.56) | HSP90AB1POLBMEN1LMNAMAPT | |
| SCHEMBL8262764 | 0.84 | HSP90AB1 (0.43) | HSP90AB1PPARGPPARACYSLTR2CYSLTR1 | |
| SCHEMBL480388 | 0.84 | CYP1A2 (0.50) | PPARGPPARACYSLTR2CYSLTR1MEN1 | |
| SCHEMBL10726758 | 0.84 | SELL (0.53) | PPARGPPARALMNAMAPTHPGD | |
| SCHEMBL30736074 | 0.84 | CYP1A2 (0.50) | PPARGPPARACYSLTR2CYSLTR1MEN1 | |
| SCHEMBL6358047 | 0.83 | GRM2 (0.46) | HSP90AB1MEN1LMNAMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105121395-A | Method to improve 1,1,3-trichloropropene and/or 3,3,3-trichloropropene selectivity during the dehydrochlorination of 1,1,1,3-tetrachloropropane | HONEYWELL INT INC | 2015-12-02 | — | — | CN | disclosed |
| CN-102161653-A | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof | ABBOTT LAB | 2011-08-24 | — | — | CN | disclosed |
| CN-101534811-A | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | ORGANON NV (NL) | 2009-09-16 | — | — | CN | disclosed |
| CN-101443327-A | Chromanylurea compounds that inhibit vanilloid receptor subtype 1(VR1) receptor and uses thereof | ABBOTT LAB (US) | 2009-05-27 | — | — | CN | disclosed |
| US-7495020-B2 | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | MERCK & CO., INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495020-B2 | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | MERCK & CO., INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495020-B2 | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | MERCK & CO., INC. (US) | 2009-02-24 | — | — | US | disclosed |
| CN-1877879-A | Barrier layer for an organic electronic device | XEROX CORP (US) | 2006-12-13 | — | — | CN | disclosed |
| US-7091230-B2 | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | MERCK & CO., INC. (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060122242-A1 | 2-Aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | MERCK SHARP & DOHME CORP. | 2006-06-08 | — | — | US | disclosed |
| WO-1997027857-A1 | ANTIDIABETIC AGENTS | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | disclosed |
| WO-1997028115-A1 | ANTIDIABETIC AGENTS | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | disclosed |
| WO-1997028137-A1 | HETEROCYCLIC DERIVATIVES AS ANTIDIABETIC AND ANTIOBESITY AGENTS | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | disclosed |
| CN-1035001-C | Substituted phenyl phenol leukotriene antagonists | LILLY CO ELI (US) | 1997-05-28 | — | — | CN | disclosed |
| CN-1088906-A | The phenyl phenol leukotriene antagonists that replaces | LILLY CO ELI (US) | 1994-07-06 | — | — | CN | disclosed |
| EP-0295882-B1 | PROCESS FOR INTERMEDIATES TO LEUKOTRIENE ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1991-08-21 | — | — | EP | disclosed |
| EP-0295882-A1 | Process for intermediates to leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1988-12-21 | — | — | EP | disclosed |
| US-4777299-A | Process for leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1988-10-11 | — | — | US | disclosed |
| EP-0028063-B1 | PHENOL DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 1984-06-13 | — | — | EP | disclosed |
| EP-0028063-A1 | Phenol derivatives, processes for their preparation and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 1981-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122242-A1 | 2-Aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | PPARA, PPARG, PPARD | HSP90AB1 877/4885PPARG 2/4885PPARA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.